BIOCRYST PHARMACEUTICALS, INC. Financials BioCryst Pharmaceuticals, Inc.
Equities
BCRX
US09058V1035
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.16 USD | 0.00% |
|
-6.09% | -30.55% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 531.5 | 1,315 | 2,492 | 2,140 | 1,227 | 858.3 | - | - |
| Enterprise Value (EV) 1 | 479.9 | 1,198 | 2,124 | 2,140 | 1,654 | 1,092 | 1,117 | 949.4 |
| P/E ratio | -3.67 x | -6.83 x | -13.4 x | -8.63 x | -5.08 x | -6.6 x | -12 x | 14.5 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 10.9 x | 73.8 x | 15.9 x | 7.9 x | 3.7 x | 2.17 x | 1.77 x | 1.48 x |
| EV / Revenue | 9.83 x | 67.3 x | 13.5 x | 7.9 x | 4.99 x | 2.76 x | 2.31 x | 1.63 x |
| EV / EBITDA | -4.86 x | -6.88 x | -12 x | -14.6 x | -16.2 x | -19.5 x | 171 x | - |
| EV / FCF | -5.34 x | -7.28 x | -14.7 x | -13.1 x | -17 x | 50.2 x | 11.5 x | 6.58 x |
| FCF Yield | -18.7% | -13.7% | -6.81% | -7.63% | -5.88% | 1.99% | 8.7% | 15.2% |
| Price to Book | 10.4 x | -68.5 x | -23.9 x | -7.32 x | -2.71 x | -1.73 x | -1.64 x | -1.69 x |
| Nbr of stocks (in thousands) | 154,059 | 176,566 | 179,936 | 186,424 | 204,809 | 206,331 | - | - |
| Reference price 2 | 3.450 | 7.450 | 13.85 | 11.48 | 5.990 | 4.160 | 4.160 | 4.160 |
| Announcement Date | 3/5/20 | 2/25/21 | 2/23/22 | 2/21/23 | 2/26/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 48.84 | 17.81 | 157.2 | 270.8 | 331.4 | 395.1 | 484.4 | 580.7 |
| EBITDA 1 | -98.73 | -174 | -176.9 | -147 | -102.1 | -56 | 6.52 | - |
| EBIT 1 | -99.46 | -174.8 | -177.7 | -148.4 | -103.7 | -43.92 | 28.12 | 118.3 |
| Operating Margin | -203.66% | -981.12% | -113.08% | -54.81% | -31.29% | -11.12% | 5.8% | 20.38% |
| Earnings before Tax (EBT) 1 | -108.9 | -182.8 | -181.8 | -244.4 | -226.2 | -137.5 | -65.76 | 66.33 |
| Net income 1 | -108.9 | -182.8 | -184.1 | -247.1 | -226.5 | -128.4 | -65.76 | 61.23 |
| Net margin | -222.99% | -1,026.35% | -117.11% | -91.25% | -68.36% | -32.49% | -13.58% | 10.54% |
| EPS 2 | -0.9400 | -1.090 | -1.030 | -1.330 | -1.180 | -0.6304 | -0.3455 | 0.2860 |
| Free Cash Flow 1 | -89.93 | -164.6 | -144.5 | -163.2 | -97.31 | 21.78 | 97.21 | 144.3 |
| FCF margin | -184.14% | -924.12% | -91.97% | -60.26% | -29.36% | 5.51% | 20.07% | 24.86% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | 1,490.8% | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 235.74% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/5/20 | 2/25/21 | 2/23/22 | 2/21/23 | 2/26/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 40.99 | 47.16 | 49.92 | 65.53 | 75.83 | 79.54 | 68.78 | 82.49 | 86.74 | 93.4 | 85.51 | 98.28 | 103 | 108.5 | 105 |
| EBITDA | -44.36 | -52.01 | -49.64 | -34.39 | -17.06 | -45.92 | -28.01 | - | - | -42.25 | - | - | - | - | - |
| EBIT 1 | -44.58 | -52.18 | -49.96 | -34.72 | -17.44 | -46.31 | -28.42 | -20.7 | -11.92 | -42.67 | -22.63 | -9.967 | -6.217 | -5.685 | -1.937 |
| Operating Margin | -108.76% | -110.64% | -100.07% | -52.98% | -23.01% | -58.22% | -41.31% | -25.1% | -13.74% | -45.68% | -26.47% | -10.14% | -6.04% | -5.24% | -1.84% |
| Earnings before Tax (EBT) 1 | -58.8 | -15.53 | -73.92 | -58 | -41 | -71.47 | -52.66 | -74.59 | -35.82 | -63.16 | -44.64 | -32.41 | -29.23 | -28.54 | -19.66 |
| Net income 1 | -58.8 | -17.78 | -74.2 | -58.86 | -42.52 | -71.54 | -53.33 | -75.33 | -36.15 | -61.73 | -42.57 | -29.97 | -26.42 | -25.93 | -19.66 |
| Net margin | -143.44% | -37.7% | -148.62% | -89.82% | -56.08% | -89.94% | -77.54% | -91.31% | -41.67% | -66.09% | -49.79% | -30.49% | -25.66% | -23.89% | -18.72% |
| EPS 2 | -0.3300 | -0.1000 | -0.4000 | -0.3200 | -0.2300 | -0.3800 | -0.2800 | -0.4000 | -0.1900 | -0.3100 | -0.2107 | -0.1510 | -0.1290 | -0.1241 | -0.0900 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/3/21 | 2/23/22 | 5/5/22 | 8/4/22 | 11/1/22 | 2/21/23 | 5/3/23 | 8/3/23 | 11/2/23 | 2/26/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 427 | 234 | 259 | 91.1 |
| Net Cash position 1 | 51.6 | 117 | 368 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -4.181 x | -4.179 x | 39.68 x | - |
| Free Cash Flow 1 | -89.9 | -165 | -145 | -163 | -97.3 | 21.8 | 97.2 | 144 |
| ROE (net income / shareholders' equity) | -249% | -1,925% | - | - | - | -34.9% | - | - |
| ROA (Net income/ Total Assets) | -67.6% | -71.7% | -52% | - | -42.5% | -32.1% | -25.2% | -15.5% |
| Assets 1 | 161.1 | 255 | 354 | - | 533.5 | 399.5 | 260.8 | -395.7 |
| Book Value Per Share 2 | 0.3300 | -0.1100 | -0.5800 | -1.570 | -2.210 | -2.400 | -2.540 | -2.460 |
| Cash Flow per Share 2 | -0.7800 | -0.8200 | -0.7900 | -0.8700 | -0.5000 | -0.4400 | -0.1200 | - |
| Capex 1 | 0.34 | 0.51 | 2.39 | 1.35 | 2.17 | 0.36 | 0.18 | 0.37 |
| Capex / Sales | 0.7% | 2.89% | 1.52% | 0.5% | 0.65% | 0.09% | 0.04% | 0.06% |
| Announcement Date | 3/5/20 | 2/25/21 | 2/23/22 | 2/21/23 | 2/26/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
4.16
USD
Average target price
12.2
USD
Spread / Average Target
+193.27%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -30.55% | 858M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- BCRX Stock
- Financials BioCryst Pharmaceuticals, Inc.
